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Background: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes constituting a large proportion
of peripheral blood T cells expressing αβ T-cell receptor in humans. In this study, we aimed to investigate their
involvement in systemic lupus erythematosus (SLE).
Methods: Peripheral blood MAIT cells from patients with SLE were assessed for their frequency, activation markers,
and cell death by flow cytometry. The correlation between plasma cytokine levels and CD69 expression on MAIT
cells was analyzed. The major histocompatibility complex class I-related protein MR1-restricted antigen-presenting
capacity of antigen-presenting cells was investigated. Cytokine-mediated activation of MAIT cells in the absence
of exogenous antigens was also examined.
Results: The frequency of MAIT cells was markedly reduced in SLE. The reduced number of MAIT cells was not
attributable to the downregulation of surface markers, but it was partially due to the enhanced cell death of MAIT
cells, possibly by activation-induced cell death. The CD69 expression levels on MAIT cells in SLE correlated with
disease activity. Moreover, monocytes from patients with SLE exhibited increased ability to induce MAIT cell
activation. The plasma concentration of interleukin (IL)-6, IL-18, and interferon (IFN)-α positively correlated with the
expression levels of CD69 on MAIT cells in SLE. MAIT cells were activated by cytokines, including IFN-α, IL-15, and
IL-12 plus IL-18, in the absence of exogenous antigens.
Conclusions: These results suggest that MAIT cells reflect the pathological condition of SLE and that their activated
status correlates with presence of disease.
Keywords: Systemic lupus erythematosus, Innate-like lymphocytes, Mucosal-associated invariant T cells, Activation
marker, Disease activity index, Antigen presentation, CytokinesBackground
Mucosal-associated invariant T (MAIT) cells are a
unique population of innate-like lymphocytes that is re-
stricted by major histocompatibility complex class I-
related protein (MR1) and expresses the semi-invariant
T-cell receptor (TCR) Vα7.2-Jα33 in humans and Vα19-
Jα33 in mice with a limited set of Vβ chains [1, 2]. Simi-
larly to other innate-like lymphocytes, such as natural
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upon activation without the need to undergo clonal ex-
pansion [3, 4]. MAIT cells were originally named after
their preferential location at mucosal tissues, where they
are involved in the first-line defense against exogenous
stimuli [2]. Interestingly, MAIT cells are absent in the
peripheral blood of germ-free mice [2]. MAIT cells have
been shown to react to antigen-presenting cells in the
presence of certain types of microbes in vitro and to
protect mice against pathogenic bacteria in vivo [5–7].
Therefore, MAIT cells are thought to recognize micro-
bial antigens, and Kjer-Nielsen et al. recently elucidatedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Characteristics of healthy control subjects and patients
with lupus
HCs Patients with SLE
Number 48 53
Females/males, n 43/5 49/4
Age, years 37.5 (28.3–43.8) 36.0 (30.0–43.0)
Disease duration, years 6.0 (1.0–11.0)
SLEDAI score 6.0 (2.0–15.5)
SLEDAI <5, n 25




Prednisone dose, mean ± SD
(mg/day)
11.0 (5.0–22.5)
Immunosuppressive agent,a n 13
Abbreviations: HCs Healthy control subjects, SLE Systemic lupus erythematosus,
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
Values are n or median (interquartile range)
aAzathioprine, cyclosporine, cyclophosphamide, mizoribine, mycophenolate
mofetil, tacrolimus
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MR1 and activate MAIT cells [8].
Other recent studies revealed that MAIT cells are
abundant in human peripheral blood and constitute be-
tween 1% and 10% of all αβT cells [4, 9]. They express
high levels of CD161, an NK receptor also known as
NKR-P1A, and exhibit effector memory phenotypes in
peripheral blood, presumably owing to their prior expos-
ure to microbial antigens from commensal bacteria.
Similarly to other innate-like T cells such as γδT cells
and iNKT cells, MAIT cells can be fully activated by cy-
tokines in the absence of exogenous antigens [10–12].
Previously, we demonstrated that murine MAIT cells
stimulated with interleukin (IL)-23 produce IL-17,
whereas IL-1β induces MAIT cell proliferation [10]. Hu-
man MAIT cells are also activated by the combination of
IL-12 and IL-18 and produce interferon (IFN)-γ. These
activation mechanisms of MAIT cells indicate that they
could be involved in various types of immune responses
besides antimicrobial immunity. Indeed, whereas MAIT
cells exacerbate joint inflammation in arthritis models,
they suppress neuroinflammation in experimental auto-
immune encephalomyelitis and colitis in a trinitrobenze-
nesulfonic acid-induced colitis model [10, 13, 14].
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by the production of autoanti-
bodies. The activation of autoreactive B and T cells is a
hallmark of lupus pathology, although other features in-
clude numerical and functional abnormalities of innate
immune cells and innate-like lymphocytes. In SLE, the
frequencies of NK cells, iNKT cells, and γδT cells are de-
creased, and the killing activity of NK cells and the cyto-
kine production of iNKT cells are reduced [15–21]. In
addition, the proliferative capacity of lupus γδT cells is
diminished [21]. Although it is not known whether these
abnormalities are a cause or consequence of the patho-
logical process underlying SLE, the activated status and
functional abnormalities are clearly associated with the
pathology.
Recently, Cho et al. reported that levels of MAIT cells
were reduced in patients with SLE [22]. MAIT cell defi-
ciency is associated with these cells’ poor responsiveness
upon activation and elevated programmed cell death
protein 1 (PD-1) expression. Numerical and functional
deficiencies of iNKT cells may also contribute to the
malfunction of MAIT cells. We also demonstrate that
the frequency of MAIT cells was markedly reduced in
patients with SLE. However, contrary to the findings of
Cho et al., we show that MAIT cells in SLE are greatly
activated and that their activation is correlated with dis-
ease activity. The reduction of MAIT cell frequency was
not due to a downregulation of surface markers, but ra-
ther was partially caused by activation-induced cell
death. We elucidate two possible mechanisms of MAITcell activation in SLE. First, we demonstrate that mono-
cytes in patients with SLE have an increased capacity to
present MR1 antigens and activate MAIT cells. Second,
we show that the plasma levels of IL-6, IL-18, and IFN-α
positively correlate with the activated status of MAIT
cells in SLE, and that MAIT cells are activated by
cytokines, including IL-18 and IFN-α, in the absence of
exogenous antigens, indicating that inflammatory cyto-
kines may also be responsible for the activation of MAIT
cells in lupus. Taken together, MAIT cells reflect the
pathological condition of SLE, and their activated status
correlates with presence of disease. These findings sug-
gest that MAIT cells may be associated with the patho-
genesis of SLE.Methods
Human samples
We obtained peripheral blood from a total of 53 patients
with SLE (49 females and 4 males, median age 36.0 years
[IQR 30.0–43.0], median disease duration 6.0 years [IQR
1.0–11.0]) diagnosed according to the American College
of Rheumatology revised criteria for SLE [23] and 48
healthy control subjects (HCs) after gaining informed
consent in accordance with local ethics committee
guidelines of Juntendo University. HCs were matched to
patients with SLE for sex and age. The characteristics of
patients with SLE and HCs are shown in Table 1. Dis-
ease activity was measured using the Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) [24],
and a SLEDAI score ≥5 was defined as active disease.
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Flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) were puri-
fied from heparinized blood by centrifugation over a
Ficoll-Paque gradient (GE Healthcare, Uppsala, Sweden).
PBMCs were incubated with Fc receptor blocking re-
agent (Miltenyi Biotec, Bergisch Gladbach, Germany),
and cell surface staining was performed using the
following monoclonal antibodies (mAbs) and tetra-
mers: TCR pan-γ/δ-fluorescein isothiocyanate (FITC),
CD8β-phycoerythrin (PE)-Texas Red electron-coupled
dye (Beckman Coulter, Indianapolis, IN, USA); CD3-
allophycocyanin (APC)-H7, CD4-APC-H7, CD8a-
APC-H7, CD3-AmCyan, CD3-BD Horizon V500 (BD
Biosciences, San Jose, CA, USA); TCR Vα7.2-PE, TCR
Vα7.2-APC, TCRγ/δ-APC, CD3-peridinin chlorophyll
(PerCP)/cyanine 5.5 (Cy5.5), CD161-PerCP/Cy5.5,
CD161-Brilliant Violet 421, CD4-Alexa Fluor 700,
CD69-Alexa Fluor 700, CD69-Brilliant Violet 605,
CD95-Brilliant Violet 421, (BioLegend, San Diego, CA,
USA); CD161-APC (eBioscience, San Diego, CA,
USA); and CD1d/PBS-57 tetramer-APC (National In-
stitutes of Health Tetramer Core Facility, Atlanta, GA,
USA). Staining with 7-aminoactinomycin D (7-AAD;
BD Biosciences) was performed to discern dead cells.
In most experiments, samples were fixed using BD stabil-
izing fixative (BD Biosciences). Intracellular staining of ac-
tive caspase-3 was performed using the caspase-3 active
form mAb apoptosis kit with FITC (BD Biosciences). Data
were acquired by fluorescence-activated cell sorting
(FACS) on an LSRFORTESSA (BD Biosciences), and the
percentages of each cell population and mean fluores-
cence intensities (MFIs) were analyzed with FlowJo soft-
ware (FlowJo LLC, Ashland, OR, USA).
Single-cell polymerase chain reaction
Cells were single-cell-sorted using the BD FACSAria II
system (BD Biosciences) into catch buffer (10 mM Tris,
pH 8.0) containing 40 U/μl of RNasin ribonuclease inhibi-
tor (Promega, Madison, WI, USA). Reverse transcriptase-
polymerase chain reaction (RT-PCR) was performed using
a four-primer mixture and the QIAGEN OneStep RT-
PCR Kit (QIAGEN, Germantown, MD, USA) following
the manufacturer’s instructions. The following primers
were used: AV7.2-AJ33-S, CTGGATGGTTTGGAGGA-
GAA; AV7.2-AJ33-AS, GCGCCCCAGATTAACTGATA;
TRAC-A, TGCCTATTCACCGATTTTGA; and TRAC-
AS, GCAGCGTCATGAGCAGATTA.
Cell culture
PBMCs were cultured in 96-well flat-bottom plates in
RPMI 1640 medium (Thermo Fisher Scientific, Waltham,MA, USA) supplemented with 10% FBS, 2 mM L-glutam-
ine, 50 U/ml penicillin, and 50 μg/ml streptomycin (all
from Thermo Fisher Scientific). PBMCs were stimulated
with either immobilized anti-CD3 mAb (OKT3, 1 μg/ml;
American Type Culture Collection, Manassas, VA, USA)
or IL-6, IL-12p70 (PeproTech, Rocky Hill, NJ, USA), IL-
13, IL-15 (BioLegend), IL-18 (Medical & Biological
Laboratories Co. [MBL], Nagoya, Japan), granulocyte-
macrophage colony-stimulating factor (GM-CSF), IFN-α
(R&D Systems, Minneapolis, MN, USA), or a major histo-
compatibility complex class I-related protein ligand
(MR1L; 10 μM). The cytokine concentrations for stimula-
tion were 50 ng/ml, except for IFN-α (100 U/ml). 7-
Methyl-8-D-ribityllumazine was synthesized following pre-
viously reported procedures [25] and used as an MR1L.Proliferation assay
PBMCs were labeled using the CellTrace Violet Cell
Proliferation Kit (Thermo Fisher Scientific) and cultured
in 96-well flat-bottom plates coated with anti-CD3 mAb
(1 μg/ml) and anti-CD28 mAb (CD28.2, 1 μg/ml; BioLe-
gend). Seven days later, cells were stained with surface
markers and 7-AAD, and CellTrace low-dividing cells or
7-AAD-positive dead cells were analyzed by FACS.Activation of human MAIT cells by MR1L
B cells or monocytes were sorted from PBMCs using
anti-CD19 or anti-CD14 microbeads (Miltenyi Biotec),
respectively, following the manufacturer’s instructions.
MAIT cells were sorted from PBMCs of HCs using the
BD FACSAria II system (BD Biosciences) or MoFlo
Astrios cell sorter (Beckman Coulter) as described else-
where [26]. B cells or monocytes (1 × 104 cells) were cul-
tured for 18 h with MAIT cells (5 × 104 cells) in the
presence of MR1L (10 μM).Cytokine measurement
Cytokine levels were measured using sandwich enzyme-
linked immunosorbent assays for IL-18 (MBL) and IFN-α
(PBL Assay Science, Piscataway, NJ, USA) or a Bio-Plex
assay (Bio-Rad Laboratories, Hercules, CA, USA) for
other cytokines.Statistical analysis
All data were analyzed using Prism 6 software (Graph-
Pad Software Inc., La Jolla, CA, USA), and differences
between the groups were analyzed using the Mann–
Whitney U test, the Kruskal-Wallis test followed by
Dunn’s multiple comparisons test, or the Wilcoxon
rank-sum test. The significance level was set at p < 0.05.
Associations between two variables were analyzed using
Spearman’s correlation.
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The frequency of MAIT cells is reduced in peripheral
blood of patients with SLE
First, by FACS analysis, we investigated the frequencies
of MAIT cells and other innate-like T cells, including
iNKT cells and γδT cells, in peripheral blood from pa-
tients with SLE. As previously reported, the proportions
of all innate-like lymphocytes examined in the study
were reduced in patients with SLE (Fig. 1a). The fre-
quency of MAIT cells was markedly reduced in patientsFig. 1 Decreased frequency of mucosal-associated invariant T (MAIT) cells i
blood mononuclear cells (PBMCs) were stained with monoclonal antibodie
tetramer, and analyzed by flow cytometry. a Percentages of MAIT cells (Vα7
natural killer T (iNKT) cells (CD3+TCRγδ−CD1d/PBS-57 tetramer+) are shown
αβT cells. Each symbol represents the value of one individual. The box plot
median. Whiskers indicate the minimum and maximum. * p < 0.05, ** p < 0
TCR use in Vα7.2 TCR+ T cells. c Representative fluorescence-activated cell s
cell populations, including MAIT cells. Single-cell amplification of TCR α con
gel electrophoresis image showing TCR segments containing Cα and AV7.2
shown. d Summary of AV7-AJ33-bearing cells in each T-cell subpopulationwith SLE (median 0.65%, IQR 0.20–1.28) compared with
that in HCs (median 3.69%, IQR 2.65–6.73) (Fig. 1a). In
contrast, the reduction of other innate-like lymphocyte
subsets was milder than that of MAIT cells (Fig. 1a).
MAIT cells can be distinguished by flow cytometry as
Vα7.2 TCR+ αβT cells with a high expression of CD161.
Because lymphocytes may downregulate surface mole-
cules, we investigated whether the reduction of MAIT
cell frequency in SLE was due to the downregulation of
the surface markers. There was no increase of CD161dimn patients with systemic lupus erythematosus (SLE). a, b Peripheral
s against CD3, T-cell receptor (TCR) γδ, Vα7.2, CD161, and CD1d/PBS-57
.2+CD161highCD3+TCRγδ−cells), γδT cells (CD3+TCRγδ+), and invariant
. b Percentages of CD161dim and CD161negative Vα7.2 TCR+ cells among
indicates the first and third quartiles, and the middle line indicates the
.01, **** p < 0.0001 (Mann–Whitney U test). c, d Invariant Vα7.2-Jα33
orting staining profile and gating strategy for single-cell sorting of T-
stant (Cα) and AV7.2-AJ33 was performed. A representative agarose
-AJ33 in each T-cell subpopulation from a healthy control (HC) are
determined by single-cell polymerase chain reaction
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compared with HCs (Fig. 1b). Next, we performed
single-cell PCR analysis for the expression of Vα7.2-Jα33
TCR to evaluate whether αβT cells expressing invariant
Vα7.2-Jα33 TCR were contaminated among other αβT
cell populations in SLE. As shown in Fig. 1d, the propor-
tions of invariant Vα7.2-Jα33 expression in CD161dim
and CD161negative cells were not increased in patients
with SLE compared with HCs. These results indicate
that the decreased frequency of MAIT cells in patients
with SLE did not result from a downregulation of sur-
face markers.
Cell death of MAIT cells is enhanced in SLE
Next, we assessed whether the reduced frequency of
MAIT cells was due to increased cell death. As expected,
the levels of both 7-AAD- and active caspase-3-positive
cells were increased in MAIT cells in patients with SLE
(median 2.79 [IQR 1.31–3.89], 2.31 [IQR 2.11–3.94], re-
spectively) (Fig. 2a) compared with the HCs (median
0.55 [IQR 0.24–1.53]; 0.73 [0.08–1.30], respectively)
(Fig. 2a), indicating that cell death is enhanced in MAIT
cells in lupus. Because FAS expression is increased on
MAIT cells in SLE (median MFI for HCs 756 AU [IQR
647–1474] vs median MFI for SLE 1879 AU [1786–
4855]) (Fig. 2a), we speculate that apoptosis occurs in
MAIT cells through activation-induced cell death. Not-
ably, MAIT cells from patients with lupus were prone toFig. 2 Enhanced cell death of lupus mucosal-associated invariant T (MAIT)
from patients with systemic lupus erythematosus (SLE) and healthy control
against CD3, T-cell receptor (TCR) γδ, Vα7.2, CD161, and CD95 (FAS). 7-Amin
ing, and surface FAS expression of MAIT cells were analyzed by fluorescenc
Violet and cultured in plates coated with anti-CD3 mAb (1 μg/ml) and anti
positive dead cells were analyzed by FACS. Each symbol represents the val
and the middle line indicates the median. Whiskers indicate the minimum a
(Mann–Whitney U test). MFI Mean fluorescence intensitydeath upon in vitro stimulation. The percentages of div-
iding cells among activated MAIT cells from patients
with SLE (median 14.60% [IQR 7.40–21.50]) were lower
than those of cells from HCs (median 42.00% [IQR
28.30–67.90]), as shown in Fig. 2b. Instead, more MAIT
cells were positive for 7-AAD after culture in SLE (me-
dian SLE 73.25 [IQR 56.65–81.50] vs median HCs 15.70
[IQR 5.30–41.60]).MAIT cells are activated in SLE, which reflects disease
activity
We next investigated the expression of CD69, an early
activation marker on MAIT cells, to verify whether
MAIT cells are activated in SLE. The percentages of
CD69+ cells among MAIT cells tended to be higher in
patients with SLE with inactive disease (median 26.70%
[IQR 16.80–38.30]) than in healthy subjects (median
11.70% [IQR 7.22–20.80]), although there was no statis-
tical difference between the two groups (Fig. 3a). In con-
trast, MAIT cells from patients with active disease
showed an increased expression of CD69 (median
29.95% [IQR 13.00–54.68]) compared with MAIT cells
in HCs. Interestingly, there was a positive correlation be-
tween the SLEDAI score and the percentage of CD69+
MAIT cells (Fig. 3c). There was no increased surface ex-
pression of CD69 on other T-cell subsets in patients
with SLE compared with HCs (Fig. 3b). These resultscells. a Freshly isolated peripheral blood mononuclear cells (PBMCs)
subjects (HCs) were stained with monoclonal antibodies (mAbs)
oactinomycin D (7-AAD) staining, intracellular active caspase-3 stain-
e-activated cell sorting (FACS). b PBMCs were labeled with CellTrace
-CD28 mAb (1 μg/ml). After 7 days, cell proliferation and 7-AAD-
ue of one individual. The box plot indicates the first and third quartiles,
nd maximum. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
Fig. 3 Mucosal-associated invariant T (MAIT) cell activation and correlation of CD69+ MAIT cell frequency with disease activity in systemic lupus
erythematosus (SLE). CD69 expression on MAIT cells (a) and other T-cell subsets (b), including γδT cells, CD4+ T cells, and CD8+ T cells, were ana-
lyzed by flow cytometry. a Representative examples of CD69 expression on MAIT cells and the percentages of CD69+ cells among each MAIT cell
population in patients with SLE are shown. The gray histogram indicates isotype control. The relative levels of CD69+ MAIT cells are increased in
patients with SLE with active disease compared with healthy control subjects (HCs). *p < 0.05, ** p < 0.01 (Kruskal-Wallis test followed by Dunn’s
multiple comparisons test). Each symbol represents the value of one individual. The box plot indicates the first and third quartiles, and the middle
line indicates the median. Whiskers indicate the minimum and maximum. c Correlations between Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) score and CD69+ MAIT cells or CD69 expression on MAIT cells. Symbols represent individual subjects. There was a positive correl-
ation between the percentages of CD69+ cells among MAIT cells and the SLEDAI score. Correlations were analyzed using Spearman’s correlation
analysis. MFI Mean fluorescence intensity
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was associated with SLE disease activity.
Monocytes from patients with SLE exert a profound effect
on MAIT cell activation capacity
To reveal the mechanisms of MAIT cell activation in
SLE, we tested MAIT cell activation by antigen-
presenting cells from patients with SLE. Monocytes or B
cells were cocultured with human MAIT cells with
MR1L for 18 h, and the surface expression of CD69 on
MAIT cells was analyzed by flow cytometry. The MFIs
of CD69 on MAIT cells cocultured with B cells from pa-
tients with SLE or from HCs were comparable. MAIT
cells cultured with monocytes from patients with SLE in
the presence of MR1L displayed higher levels of CD69than did cells cultured with monocytes from HCs
(Fig. 4a). The enhanced antigen-presenting capacity was
observed for monocytes from patients with both active
and inactive disease. Coculture with B cells or mono-
cytes without MR1L did not activate MAIT cells.
To elucidate the mechanism by which monocytes from
patients with SLE exerted this increased MAIT cell-
activating capacity, we next measured concentrations of
19 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-
10, IL-12, IL-13, IL-15, IL-17, IL-18, IL-23, GM-CSF,
granulocyte colony-stimulating factor, IFN-α, IFN-γ, and
tumor necrosis factor [TNF]-α), including those known
to activate MAIT cells. The concentrations of IL-12 and
TNF-α were increased in the culture with MR1L and
monocytes from patients with SLE (Fig. 4b). Other
Fig. 4 Augmented mucosal-associated invariant T (MAIT) cell-activating capacity of monocytes from patients with systemic lupus erythematosus
(SLE). a Monocytes or B cells were sorted from peripheral blood mononuclear cells (PBMCs) and cocultured with allogenic MAIT cells in the ab-
sence or presence of major histocompatibility complex class I-related protein ligand (MR1L; 10 μM). After 18 h, the surface expression of CD69 on
MAIT cells was analyzed by flow cytometry (a), and the cytokine levels in the culture supernatants were measured by enzyme-linked immunosorb-
ent assay or Bio-Plex assay (b). Each symbol represents the mean fluorescence intensity (MFI) of CD69 on cells (a) or the concentration of interleu-
kin (IL)-12 and tumor necrosis factor (TNF)-α (b) from cultures with antigen-presenting cells from healthy control subjects (HCs), patients with SLE
with inactive disease (closed circles), or active disease (open triangles). Data from the same experiment are connected by lines. Statistical analysis
was performed using the Wilcoxon matched-pairs signed-rank test, * p < 0.05, ** p < 0.01
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able or comparable between cultures with monocytes
from either patients with SLE or HCs (data not shown).
These results suggest that the enhanced MAIT cell-
activating capacity of monocytes from patients with SLE
was associated with their augmented IL-12 production.Cytokine-mediated activation of MAIT cells may occur in
active SLE
CD69 expression on MAIT cells was positively corre-
lated with disease activity. However, monocytes from pa-
tients with active and stable disease equally activated
MAIT cells (Fig. 4a). Therefore, we assumed that there
were other factors responsible for CD69 upregulation on
MAIT cells in patients with active SLE. Human MAIT
cells and γδT cells are known to be activated by cyto-
kines such as IL-12 and IL-18. We hypothesized that the
activation of these cells may be due to cytokines that are
increased in patients with active lupus. As shown in
Fig. 5a, the plasma level of IL-18 negatively correlated
with the percentage of MAIT cells in SLE. We also
found that the plasma concentrations of IL-6, IL-18, and
IFN-α positively correlated with the CD69 expression on
MAIT cells.
Next, we tested which cytokines that were elevated in
plasma from patients with SLE could activate MAIT cells
upon in vitro stimulation. As previously reported,
in vitro stimulation with IL-15 and IL-12 plus IL-18 in-
duced CD69 upregulation on MAIT cells (Fig. 5b).
MAIT cells were also strongly activated by IFN-α, an im-
portant factor in lupus pathogenesis. In contrast,cytokines such as IL-6 had little effect on MAIT cells
(Fig. 5b).
Discussion
In the present study, we demonstrated that MAIT cell
levels are decreased in the peripheral blood of patients
with SLE, and that the reduction of MAIT cells in the
periphery was due, at least in part, to activation-induced
cell death. MAIT cells in SLE are activated, and the ex-
pression of the activation marker CD69 on these cells
clearly correlated with disease activity. We revealed that
MAIT cell activation was associated with an increased
activation capacity of monocytes from patients with
lupus. We also demonstrated that the elevated levels of
certain inflammatory cytokines correlated with the acti-
vated state of MAIT cells in SLE, and that this may elicit
the cytokine-mediated activation of MAIT cells. Taken
together, our data reveal that MAIT cells reflect the
pathogenesis of SLE and that their activated status
strongly correlates with presence of disease.
Poor responses of iNKT cells and γδT cells upon stimu-
lation have been reported in SLE, and the low responsive-
ness of iNKT was shown to be due to cell-intrinsic
impairment in these cells, but not antigen-presenting cells
[17, 18, 20, 21]. Authors of a previous report on lupus
MAIT cells showed that the elevated PD-1 expression was
accompanied by impaired IFN-γ production by these cells
[22]. In our study, MAIT cells from patients with SLE also
proliferated poorly upon activation, and this may also be
due to PD-1 expression on lupus MAIT cells. However,
because they expressed high levels of CD69 and FAS, we
speculated that MAIT cells were already activated in vivo
Fig. 5 Cytokine-mediated activation of mucosal-associated invariant T (MAIT) cells. a Correlation between the plasma levels of cytokines with the
percentage of MAIT cells or CD69 expression on MAIT cells was examined using Spearman’s correlation. Each symbol represents the value of one
individual. b MAIT cell activation upon cytokine stimulation was analyzed. Peripheral blood mononuclear cells (PBMCs) from healthy volunteers
were cultured in plates coated with anti-CD3 monoclonal antibody or in the presence of major histocompatibility complex class I-related protein
ligand or cytokines, as indicated. After 18 h, CD69 expression was analyzed on MAIT cells stimulated or unstimulated. Closed histograms indicate
isotype control. Values in the graphs indicate the percentages of CD69+ cells among stimulated MAIT cells. Representative data from three inde-
pendent experiments are shown. GM-CSF Granulocyte-macrophage colony-stimulating factor, IFN Interferon, IL Interleukin, MFI Mean fluorescence
intensity, TNF Tumor necrosis factor
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in vitro. We revealed that monocytes exhibited an en-
hanced MR1-restricted antigen-presenting capacity in
patients with SLE. As MR1-restricted antigens are vitamin
B metabolites originating from biosynthetic pathways
present in various types of microbes, including indigenous
bacteria, lupus monocytes may be exposed to such anti-
gens and subsequently induce activation of MAIT cells.
The CD69 expression on MAIT cells was markedly
upregulated in patients with active disease, but there
was a trend of increased CD69 expression on MAITcells even in patients with inactive disease. This sug-
gests that chronic activation of MAIT cells may under-
lie the pathogenesis of SLE. Monocytes exhibit an
enhanced antigen-presenting capacity, in both patients
with active disease and those with inactive disease, and
this may be responsible for the chronic activation of
MAIT cells in SLE. CD69 expression on MAIT cells in
patients with lupus positively correlated with plasma
concentrations of IL-6, IL-18, and IFN-α. Thus, once
robust inflammation occurs, MAIT cells are fully acti-
vated by cytokines, which are highly expressed in active
Chiba et al. Arthritis Research & Therapy  (2017) 19:58 Page 9 of 10disease, and this in turn causes CD69 upregulation on
MAIT cells.
MAIT cell deficiency in the peripheral blood could be re-
lated to the use of immunosuppressive agents, including
corticosteroids [26]. Cho et al. showed that there was no
correlation between MAIT cell frequencies and use of ste-
roids or immunosuppressive drugs in patients with SLE. In
this study, we also did not observe a correlation between
the dose of corticosteroid and the percentage of MAIT cells
or CD69 expression on MAIT cells. Reduced frequency of
MAIT cells in peripheral blood has previously been demon-
strated in patients with other autoimmune diseases, inflam-
matory disorders, and infectious diseases [5, 22, 27–33]. In
many cases, the reduction of peripheral blood MAIT cells
appears to be due to their migration into the inflamed
tissues because MAIT cells have a propensity to migrate to
the site of inflammation. Notably, MAIT cells constitutively
express high levels of chemokine receptors such as C-C
chemokine receptors CCR5 and CCR6 [9, 27]. IL-18-
stimulated MAIT cells upregulate the surface expression of
very late antigen-4, an integrin that mediates T-cell migra-
tion through its interaction with vascular cell adhesion
molecule-1 (VCAM-1) [12]. Indeed, MAIT cells accu-
mulate in lesions of patients with multiple sclerosis,
rheumatoid arthritis, inflammatory bowel diseases, and
mycobacterial infection [5, 12, 22, 28, 30, 34], and the acti-
vated status of MAIT cells positively correlated with both
the plasma levels of IL-18 and disease activity in ulcerative
colitis [28]. The reduction of MAIT cell frequency was re-
lated to the elevated serum concentration of IL-18 in mul-
tiple sclerosis [12]. Urinary levels of IL-18 and VCAM-1
were reported to be increased and associated with patho-
logical events in lupus nephritis [35, 36], so MAIT cells
may also migrate into inflamed tissues in SLE.
Previously, we demonstrated that human MAIT cells
exerted suppressive activity against IFN-γ production by
other T cells [27]. However, under inflammatory condi-
tions, MAIT cells produced more proinflammatory cyto-
kines than anti-inflammatory cytokines. Human adipose
tissue MAIT cells produced IL-10, but in obese patients,
they produced little IL-10 and more IL-17 [37, 38].
MAIT cells produce higher levels of IL-17 in patients with
inflammatory diseases, including ulcerative colitis, anky-
losing spondylitis, diabetes, and obesity [28, 29, 36–38].
Thus, it is possible that MAIT cells recruited to in-
flamed sites contribute to the organ damage in SLE.
Further investigations using animal models are in pro-
gress to elucidate the role of MAIT cells in the
pathogenesis of lupus.
Conclusions
This study indicates that MAIT cells are affected by in-
flammatory conditions in SLE and that their activated
status reflects disease activity. These findings suggest thepossible involvement of MAIT cells in the pathogenesis
of SLE.
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